end-stage renal disease
Conditions
Interventions
intervention group:Coenzyme Q10 400mg
placebo:placebo
Sponsors
the 306th Hospital of Chinese PLA
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Patients receiving thrice weekly hemodialysis for at least 3 months; aged more than 18 and less than 85 years; Life expectancy greater than 1 year.
Exclusion criteria
Exclusion criteria: Poor adherence of dialysis or medications; severe systemic or local infection; malignancy; kidney transplant less than 12 months before study enrollment; hospitalization within 30 days; history of a major atherosclerotic event within 3 months; pregnancy or lactation; current use antioxidant other than vitamin C; use of hemodialysis catheter.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LV systolic function;cardiac diastolic function;myocardial performance index;endothelial-dependent flow-mediated vasodilation of the brachial artery; | — |
Secondary
| Measure | Time frame |
|---|---|
| death or hospitalization due to cardiovascular events;all-cause mortality;chang of Coenzyme Q10 concentration; ratio of reduced Coenyme Q10 (ubiquinol) to oxidized Coenzyem Q10 (ubiquinone);oxidative stress markers;left ventricular mass index; | — |
Countries
China
Contacts
Public ContactJianjun Gao
The 306th Hospital of Chinese PLA
Outcome results
None listed